{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:29:49Z","timestamp":1794360589066,"version":"4.9.0"},"reference-count":87,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2023,2,1]]},"DOI":"10.1080\/14712598.2023.2169070","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T13:41:27Z","timestamp":1674135687000},"page":"133-143","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Next steps for the optimization of exon therapy for Duchenne muscular dystrophy"],"prefix":"10.1080","volume":"23","author":[{"given":"Galina","family":"Filonova","sequence":"first","affiliation":[{"name":"Leiden University, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-654X","authenticated-orcid":false,"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0657-1"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01267-2"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01339-3"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01512-2"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1261\/rna.653607"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1832462"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1033.2003.03555.x"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2014.0506"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2013.0454"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.07.001"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302313"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.72"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61737-982-6_20"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21627"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2011.06.770"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073108"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011367"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70195-4"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.579"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.10.004"},{"key":"cit0023","unstructured":"Kyndrisa: Withdrawal of the marketing authorisation application [Internet]. 2016 [cited 2022 Oct 24]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/kyndrisa"},{"key":"cit0024","unstructured":"Declines FDA Approval for Drisapersen in DMD [Internet]. 2016 [cited 2022 Oct 24]. Available from: https:\/\/www.medscape.com\/viewarticle\/857406"},{"key":"cit0025","unstructured":"Wave life sciences announces discontinuation of suvodirsen development for Duchenne muscular dystrophy [internet]. 2019 [cited 2022 Oct 24]. Available from: https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-announces-discontinuation-suvodirsen"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.939"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.39"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42523-0"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac018"},{"key":"cit0030","unstructured":"Wave Life Sciences Announces Initiation of Dosing in Phase 1b\/2a clinical trial of WVE-N531 in Duchenne muscular dystrophy [internet]. 2021 [cited 2022 Oct 24]. Available from: https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-announces-initiation-dosing-phase-1b2a"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1093\/nass\/1.1.241"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.3390\/genes8020067"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3390\/cimb43030090"},{"key":"cit0034","unstructured":"Daiichi Sankyo Announces the Results Summary of Phase 1\/2 Clinical Trial in Japan for DS-5141 [Internet]. 2021 [cited 2022 Oct 24]. Available from: https:\/\/www.daiichisankyo.com\/media\/press_release\/detail\/index_4112.html"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70211-X"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60756-3"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23982"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005680"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555"},{"key":"cit0040","unstructured":"FDA grants accelerated approval to first drug for Duchenne muscular dystrophy [Internet]. 2016 [cited 2022 Oct 24]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23561"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210643"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009233"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2021.0043"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.07.248"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0713"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"cit0048","unstructured":"Approves Targeted FDA Treatment for rare Duchenne muscular dystrophy mutation [internet]. 2020 [cited 2022 Oct 24]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.3233\/JND-220811"},{"key":"cit0050","unstructured":"Study shows the efficacy of antisense oligonucleotide-based exon 44 skipping drug, NS-089\/NCNP-02, for patients with Duchenne muscular dystrophy (DMD) [Internet]. 2022 [cited 2022 Oct 24]. Available from: https:\/\/www.ncnp.go.jp\/topics\/2022\/20220317e.html"},{"key":"cit0051","unstructured":"NS pharma pipeline [Internet]. [cited 2022 Oct 24]. Available from: https:\/\/www.nspharma.com\/pipeline"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2010.02.012"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.08.019"},{"key":"cit0054","unstructured":"Clinical Update: Results from 30 mg\/kg cohort of MOMENTUM study of SRP-5051 for Duchenne muscular dystrophy [internet]. 2021 [cited 2022 Oct 24]. Available from: https:\/\/investorrelations.sarepta.com\/events\/event-details\/clinical-update-results-30-mgkg-cohort-momentum-study-srp-5051-duchenne"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-021-03184-z"},{"key":"cit0056","unstructured":"Sarepta therapeutics announces that FDA has lifted its clinical hold on SRP-5051 for the treatment of Duchenne muscular dystrophy [Internet]. 2022 [cited 2022 Oct 24]. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-fda-has-lifted-its-clinical-hold"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.06.036"},{"key":"cit0058","unstructured":"A novel enhanced delivery oligonucleotide (EDO) therapeutic demonstrates considerable potential in treating Duchenne muscular dystrophy [Internet]. [cited 2022 Oct 24]. Available from: https:\/\/pepgen.com\/wp-content\/uploads\/2022\/02\/PepGen_A-novel-enhanced-delivery-oligonucleotide-EDO-therapeutic.pdf"},{"key":"cit0059","unstructured":"PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the treatment of Duchenne muscular dystrophy [Internet]. 2022 [cited 2022 Oct 24]. Available from: https:\/\/investors.pepgen.com\/news-releases\/news-release-details\/pepgen-announces-first-participant-dosed-phase-1-clinical-trial"},{"key":"cit0060","unstructured":"PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the treatment of Duchenne muscular dystrophy [internet]. 2022 [cited 2022 Oct 24]. Available from: https:\/\/investors.pepgen.com\/news-releases\/news-release-details\/pepgen-reports-positive-data-phase-1-trial-pgn-edo51-treatment"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1021\/bi5004102"},{"key":"cit0062","unstructured":"Entrada therapeutics presents new data supporting its growing pipeline of endosomal escape vehicle (EEV\u2122) Therapeutics at TIDES USA 2022 [Internet]. 2022 [cited 2022 Oct 24]. Available from: https:\/\/ir.entradatx.com\/news-releases\/news-release-details\/entrada-therapeutics-presents-new-data-supporting-its-growing"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac641"},{"key":"cit0064","unstructured":"Avidity biosciences pipeline overview [Internet]. [cited 2022 Oct 24]. Available from: https:\/\/www.aviditybiosciences.com\/pipeline\/pipeline-overview\/"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.011"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.255"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1006\/scdb.1997.0182"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-004-4190-0"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.9.4929"},{"issue":"21","key":"cit0071","first-page":"1317","volume":"32","author":"Lesman D","year":"2021","journal-title":"Hum Gene Ther"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.181"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104297"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.04.025"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2010.00190.x"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3628"},{"key":"cit0077","unstructured":"Nationwide researchers announce restoration of full-length dystrophin in humans [internet]. 2022 [cited 2022 Oct 24]. Available from: https:\/\/cureduchenne.org\/all-news\/nationwide-researchers-announce-restoration-of-full-length-dystrophin-in-humans\/"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.09.008"},{"key":"cit0079","unstructured":"Notice regarding impairment loss for products under development [internet]. 2022 [cited 2022 Oct 24]. Available from: https:\/\/www.astellas.com\/en\/news\/25731"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00012.2014"},{"issue":"1","key":"cit0081","first-page":"38","volume":"91","author":"Lurio JG","year":"2015","journal-title":"Am Fam Physician"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00242-6"},{"key":"cit0083","unstructured":"PPMD submits RUSP nomination package for duchenne muscular dystrophy [Internet]. 2022 [cited 2022 Oct 24]. Available from: https:\/\/www.parentprojectmd.org\/ppmd-submits-rusp-nomination-package-for-duchenne-muscular-dystrophy\/"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.02.009"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232870"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0408-z"},{"key":"cit0087","doi-asserted-by":"crossref","unstructured":"Straub V, Mercuri E, Aartsma-Rus A, et al. Report on the workshop: meaningful outcome measures for Duchenne muscular dystrophy, London, UK, 30\u201331 January 2017. Neuromuscular Disorders. 2018;28(8):690\u2013701.","DOI":"10.1016\/j.nmd.2018.05.013"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2023.2169070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T09:17:43Z","timestamp":1678267063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2023.2169070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"alternative-id":["10.1080\/14712598.2023.2169070"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2023.2169070","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}